GlassScriptPhysician profile
Eugene Chester Mcdanald
NPI 1528052859
$1,255.04
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $61.07 · 2021: $363 · 2022: $439.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.10 | 2019-2022 | |
| Amgen INC. | $380.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.15 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $34.92 | 2020 | |
| Sobi, INC | $25.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.86 | 2021 | |
| Janssen Biotech, INC. | $16.77 | 2019 | |
| Pfizer INC. | $12.72 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.97 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Mcdanald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.